# Ysios Capital Partners

Ysios Capital Partners is a Private Equity based in Donostia-San Sebastian, Spain.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Donostia-San Sebastian, Spain
- **Region:** Europe
- **Address:** Donostia-San Sebastian, Spain
- **Founded:** 2008
- **Assets under management:** >€400M (per the firm, 2026)
- **Website:** www.ysioscapital.com
- **LinkedIn:** linkedin.com/company/ysios-capital

## Regulatory record

- **Reports private funds:** No

## About

Ysios Capital is a major European venture capital firm and leading life sciences investor financing highly innovative biotech companies worldwide. The firm provides biotech ventures with resources to develop novel therapies for indications with high unmet medical needs, focusing exclusively on innovative therapeutic drugs. It fosters positive impact on patients and society by funding transformative treatments.

## Sectors

- Biotechnology
- Digital Health
- Therapeutics
- Medical Devices
- Diagnostics

## Offices

- Barcelona, Spain

## People

- Joël Jean-Mairet — Partner
- Julia Salaverría — Partner
- Karen Wagner — Partner
- Joan Perelló — Partner
- Cristina Garmendia — Partner
- Jordi Xiol — Partner
- Guillem Laporta — Partner
- Thomas Harth — Partner
- Arturo Urrios — Partner
- Iñigo López-Huerta — Partner

## Questions

### Does Ysios participate in fund commitments or only direct deals?

Ysios invests directly into private biotech companies and does not operate as a fund-of-funds allocator. Its disclosures show equity positions in portfolio companies at the board level, with a consistent pattern of direct lead or co-lead investments. The firm has not disclosed any LP commitments to other venture funds; its model is direct therapeutic company-building.

### What investment stages does Ysios typically target?

Ysios invests from seed through pre-IPO, with a concentration on early-stage and expansion-stage private biotech companies (per Altss research record, 2026). The firm's strategy includes spin-off vehicles and company creation via the InceptionBio fund, covering the earliest phases of therapeutic development. It maintains positions through later rounds, as evidenced by retained stakes in portfolio companies that subsequently listed on NASDAQ, including Aura Biosciences and Mineralys Therapeutics.

### Which therapeutic areas does Ysios explicitly focus on?

The firm focuses exclusively on novel therapeutics for indications with high unmet medical need, spanning oncology (Adcendo, LAVA Therapeutics), CNS disorders (Synendos, Minoryx), cardiovascular conditions (CorWave, Mineralys Therapeutics), ophthalmology (SparingVision), metabolic disease (NorthSea Therapeutics) and reproductive medicine (ReproNovo). This therapeutic breadth within a single asset-class constraint — only drug and biologic developers — means Ysios operates as a sector-specialist rather than a platform generalist.

## Related profiles

- [YS Capital Partners](https://altss.com/profile/ys-capital-partners)
- [Y Soft Venture Capital](https://altss.com/profile/y-soft-venture-capital)

---

Last updated: 2026-08-11T15:08:42.881Z

Canonical page: https://altss.com/profile/ysios-capital-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology